Resistance costs and future drug options of antiretroviral therapies: Analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort

HIV Clinical Trials

Volumn 8, Issue 1, 2007, Pages 9-18

  Maggiolo, Franco ^a   Ripamonti, Diego ^a   Airoldi, Monica ^a   Callegaro, Annapaola ^a   Arici, Claudio ^a   Ravasio, Veronica ^a   Bombana, Enrico ^a   Goglio, Antonio ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Drug sequencing; FDO; First line failure; Future drug option; HAART; Resistance; Virologic failure

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG CHOICE; DRUG COST; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 34047215574     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0801-9     Document Type: Article

References (34)

1. Montaner JS, Reiss P, Cooper D, et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS Trial. Italy, the Netherlands, Canada and Australia Study. JAMA. 1998;279:930-937.
2. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl J Med. 1999;341:1865-1873.
3. Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS. 2000;14:1591-1600.
4. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. New Engl J Med. 2006;354:251-260.
5. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Ther. 2001;6(suppl 3):25-44.
6. Kuritzkes DR, Basset RL, Hazelwood D, Barret H, Rhodes RA, Young RK, Johnson VA, for the Adult ACTG 306 and 370 Teams. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr. 2004;36:600-603.
7. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996;10:975-981.
8. Maguire M, Gartland M, Moore S, et al. Absence of zidovudine resistance in antiretroviral-naïve patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS. 2000;14:1195-1201.
9. Marcelin AG, Delaguerre C, Wirden M, Viegas P, Simon A, Katlama C, Calves V. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol. 2004;72:162-165.
10. Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr. 2004;37:S36-43.
11. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four drug regimens and pairs of sequential three drug regimens as initial therapy for HIV-1 infection. New Engl J Med. 2003;349:2304-2315.
12. Tebas P, Patric AK, Kane EM, Klebert MK, Simpson JH, Erice A, Powderly WG, Henry K. Virologic response to a ritonavir-saquinavir containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23-28.
13. Katlama C, Schneider L, Agher R, Delaguerre C, Calvez V, Legrand M, Tubiana R. Ritonavir/amprenavir combination therapy in HIV infected patients who failed several protease inhibitor containing regimens. AIDS. 2000;14(suppl 4):S28.
14. Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, De Gruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003;188:1001-1008.
15. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006;41:323-331.
16. Maggiolo F, Callegaro A, Airoldi M, Ravasio V, Ripamonti D, Gregis G, Suter F. Evaluation of 3 expert systems for genotypic analysis. In: Program and abstracts of the Eighth International Congress on Drug Therapy in HIV Infection; November 2006; Glasgow, UK. Abstract P213.
17. Centers for Disease Control and Prevention. 1993 revised system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:9-12.
18. Lucas GN, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
19. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
20. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. November 10, 2003. Available at: www.hivatis.org. Last accessed January 2006.
21. De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis. 2003;187:1934-1943.
22. Kijak GH, Rubio AE, Pampuro SE, et al. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med. 2003;4:72-78.
23. Sturmer M, Doerr HW, Staszewski S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antiviral Ther. 2003;8:239-244.
24. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. JAIDS. 2005;40:404-412.
25. Youle M, Staszewski S, Clotet B, et al. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV Clin Trials. 2006;7:86-96.
26. Montaner J, Guimaraes D, Chung J, Gaffor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials. 2005;6:281-290.
27. Stanford University. Stanford HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu. Last accessed June 30, 2006.
28. Maggiolo F, Callegaro A, Ripamonti D, et al. Genotypic mutations in patients failing HAART with low level viremia. Presented at: 16th IAC; August 2006; Toronto, Canada. Abstract THPE0100.
29. Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV 1 isolated from zidovudine-naïve patients experiencing viremia on stavudine containing regimens. AIDS Res Human Retroviruses. 2001;17:1107-1115.
30. Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr. 2004;37(suppl 1):S36-S43.
31. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue exposure. Antiviral Ther. 2001;6(suppl 3):25-44.
32. Lange J. A rationale approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm. Antiviral Ther. 2001;6(suppl 3):45-54.
33. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
34. Klein MB, Willemot P, Murphy T, Lalonde RG. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS. 2004;18:1895-1904.